ArticleDrug metabolism and disposition: the biological fate of chemicals2021
Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds.
Open access · hybridAbstract read
In one paragraph
Article in Drug metabolism and disposition: the biological fate of chemicals, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma.Cancer chemotherapy and pharmacology · 2026Article
- Prediction variability in physiologically based pharmacokinetic modeling of tissue disposition under deep uncertainty.NPJ systems biology and applications · 2026Article
- Physiologically Based Pharmacokinetic Modeling to Predict Human Pharmacokinetics of a Novel Mithramycin Analog for Ewing Sarcoma.Research square · 2026Article
- Advancing the development of deep learning and machine learning models for oral drugs through diverse descriptor classes: a focus on pharmacokinetic parameters (Vdss and PPB).Molecular diversity · 2026Article
- Development of physiologically based liver distribution model that incorporates intracellular lipid partitioning and binding to fatty acid binding protein 1.The Journal of pharmacology and experimental therapeutics · 2026Article
- From Population-Based PBPK to Individualized Virtual Twins: Clinical Validation and Applications in Medicine.Journal of clinical medicine · 2026Review
- Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters-In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling.Clinical and translational science · 2026Article
- Development of Physiologically Based Liver Distribution Model that Incorporates Intracellular Lipid Partitioning and Binding to Fatty Acid Binding Protein 1 (FABP1).bioRxiv : the preprint server for biology · 2026Article
- Article
- Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling.Advanced drug delivery reviews · 2025Review
- Dicloxacillin and flucloxacillin inhibit hepatic uptake transporters -in vitro investigations and physiologically based pharmacokinetic modelling.bioRxiv : the preprint server for biology · 2025Article
- Computational approaches for toxicology and Pharmacokinetic properties prediction.Journal of pharmacokinetics and pharmacodynamics · 2025Review
- ADME of Bromo-DragonFLY as an example of a new psychoactive substance (NPS) - application of in Silico methods for prediction: absorption, distribution, metabolism and excretion.Scientific reports · 2025Article
- Establishing a Pharmacoinformatics Repository of Approved Medicines: A Database to Support Drug Product Development.Molecular pharmaceutics · 2025Article
- Prediction of human pharmacokinetic parameters incorporating SMILES information.Archives of pharmacal research · 2024Article
- Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.Molecular cancer · 2024Article
- A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans.Pharmaceutical research · 2024Review
- Review
- Inter-Species Pharmacokinetic Modeling and Scaling for Drug Repurposing of Pyronaridine and Artesunate.International journal of molecular sciences · 2024Article
- Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Neha MuradGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Kishore K PasikantiGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.) Kishore.k.pasikanti@gsk.com.ORCID 0000-0002-3206-0492
Benjamin D MadejGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Amanda MinnichGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Juliet M McComasGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Sabrinia CrouchGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Joseph W PolliGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Andrew D WeberGlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
Lawrence Livermore National Laboratory · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MNCI NIH HHS 75N91019D00024
Abstract
Volume of distribution at steady state (V
Indexed as
Pharmaceutical PreparationsPharmacokineticsComputer SimulationDrug DiscoveryHumansMolecular StructureTissue DistributionPharmaceutical Preparations
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.